This is so cool! The results suggested that sorafenib “significantly and dose-dependently reversed cardiopulmonary remodeling and PAH at even a low dose (10 mg/kg).” The researchers believe “a low-dose sorafenib therapy may be a suitable therapeutic agent for PAH.” This is exciting, especially because this medication is already used in humans to treat cancer. I hope the trial advances quickly.
Developments like this give me hope that a cure for PH is on its way. What kind of research developments do you look for?
There are lots of trials done on medications already being used to treat PH, but I’m most excited about new medications or new pathways to target. What gets you excited?
Pulmonary Hypertension News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.